Condition: Posaconazole · Pharmacokinetics · Invasive Candidiases · Sponsor: Melbourne Health
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
This description comes directly from the study's public registry record.
Monica Slavin, Prof · 61 3 9342 9403 · monica.slavin@mh.org.au
Tseng Lau, PhD · 61 3 9342 8274 · tseng.lau@mh.org.au
Always discuss trial participation with your own doctor first.
| Melbourne Health | Parkville, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03717623